Patents by Inventor Masataka TANIMOTO
Masataka TANIMOTO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240165118Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: ApplicationFiled: January 30, 2024Publication date: May 23, 2024Inventors: Brendan Mark JOHNSON, Lynn SEELY, Paul N. MUDD, JR., Susan WOLLOWITZ, Mark HIBBERD, Masataka TANIMOTO, Vijaykumar Reddy RAJASEKHAR, Mayukh Vasant SUKHATME
-
Patent number: 11957684Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: GrantFiled: July 15, 2022Date of Patent: April 16, 2024Assignees: Sumitomo Pharma Switzerland GmbH, Takeda Pharmaceutical Company LimitedInventors: Brendan Mark Johnson, Lynn Seely, Paul N. Mudd, Jr., Susan Wollowitz, Mark Hibberd, Masataka Tanimoto, Vijaykumar Reddy Rajasekhar, Mayukh Vasant Sukhatme
-
Patent number: 11918583Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: GrantFiled: July 15, 2022Date of Patent: March 5, 2024Assignees: Sumitomo Pharma Switzerland GmbH, Takeda Pharmaceutical Company LimitedInventors: Brendan Mark Johnson, Lynn Seely, Paul N. Mudd, Jr., Susan Wollowitz, Mark Hibberd, Masataka Tanimoto, Vijaykumar Reddy Rajasekhar, Mayukh Vasant Sukhatme
-
Patent number: 11793812Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: GrantFiled: May 11, 2021Date of Patent: October 24, 2023Assignees: Sumitomo Pharma Switzerland GmbH, Takeda Pharmaceutical Company LimitedInventors: Brendan Mark Johnson, Lynn Seely, Paul N. Mudd, Jr., Susan Wollowitz, Mark Hibberd, Masataka Tanimoto, Vijaykumar Reddy Rajasekhar, Mayukh Vasant Sukhatme
-
Publication number: 20220370462Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: ApplicationFiled: July 15, 2022Publication date: November 24, 2022Inventors: Brendan Mark JOHNSON, Lynn SEELY, Paul N. MUDD, JR., Susan WOLLOWITZ, Mark HIBBERD, Masataka TANIMOTO, Vijaykumar Reddy RAJASEKHAR, Mayukh Vasant SUKHATME
-
Publication number: 20210401841Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: ApplicationFiled: May 11, 2021Publication date: December 30, 2021Inventors: Brendan Mark JOHNSON, Lynn SEELY, Paul N. MUDD, JR., Susan WOLLOWITZ, Mark HIBBERD, Masataka TANIMOTO, Vijaykumar Reddy RAJASEKHAR, Mayukh Vasant SUKHATME
-
Patent number: 11033551Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: GrantFiled: March 29, 2019Date of Patent: June 15, 2021Assignees: Myovant Sciences GmbH, Takeda Pharmaceutical Company LimitedInventors: Brendan Mark Johnson, Lynn Seely, Paul N. Mudd, Jr., Susan Wollowitz, Mark Hibberd, Masataka Tanimoto, Vijaykumar Reddy Rajasekhar, Mayukh Vasant Sukhatme
-
Publication number: 20190262346Abstract: Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis.Type: ApplicationFiled: March 29, 2019Publication date: August 29, 2019Inventors: Brendan Mark JOHNSON, Lynn SEELY, Paul N. MUDD, JR., Susan WOLLOWITZ, Mark HIBBERD, Masataka TANIMOTO, Vijaykumar Reddy RAJASEKHAR, Mayukh Vasant SUKHATME